JP Morgan Chase’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-419,221
| Closed | -$25.1M | – | 5972 |
|
|
2019
Q4 | $25.1M | Buy |
419,221
+289,319
| +223% | +$10.9M | ﹤0.01% | 1418 |
|
|
2019
Q3 | $3.65M | Buy |
129,902
+6,006
| +5% | +$205K | ﹤0.01% | 2957 |
|
|
2019
Q2 | $4.61M | Sell |
123,896
-4,370
| -3% | -$168K | ﹤0.01% | 2707 |
|
|
2019
Q1 | $5M | Buy |
128,266
+7,114
| +6% | +$204K | ﹤0.01% | 2582 |
|
|
2018
Q4 | $2.58M | Buy |
121,152
+3,868
| +3% | +$99.8K | ﹤0.01% | 3105 |
|
|
2018
Q3 | $4.64M | Buy |
117,284
+3,331
| +3% | +$124K | ﹤0.01% | 2801 |
|
|
2018
Q2 | $4.35M | Sell |
113,953
-788
| -0.7% | -$29.2K | ﹤0.01% | 2796 |
|
|
2018
Q1 | $3.45M | Sell |
114,741
-7,403
| -6% | -$251K | ﹤0.01% | 2880 |
|
|
2017
Q4 | $3.82M | Buy |
122,144
+44,944
| +58% | +$1.23M | ﹤0.01% | 2897 |
|
|
2017
Q3 | $2.29M | Sell |
77,200
-6,805
| -8% | -$148K | ﹤0.01% | 3074 |
|
|
2017
Q2 | $1.61M | Sell |
84,005
-25,920
| -24% | -$414K | ﹤0.01% | 3175 |
|
|
2017
Q1 | $1.87M | Sell |
109,925
-13,915
| -11% | -$225K | ﹤0.01% | 3080 |
|
|
2016
Q4 | $2.26M | Sell |
123,840
-6,726
| -5% | -$116K | ﹤0.01% | 2984 |
|
|
2016
Q3 | $2.33M | Buy |
+130,566
| New | +$1.98M | ﹤0.01% | 2705 |
|
JP Morgan Chase's BOLD Position: Q1 2020 in Review
JP Morgan Chase sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 419,221 shares — an estimated $25.1M sold.
JP Morgan Chase first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $25.1M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- JP Morgan Chase reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- JP Morgan Chase sold 419,221 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $25.1M.
- JP Morgan Chase first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- JP Morgan Chase's Audentes Therapeutics, Inc position peaked at $25.1M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on JP Morgan Chase's 13F filing for Q1 2020, filed 12 May 2020.